PneumoWave PneumoWave
  • Company
    • Company Overview
    • Team
    • Board
  • Approach
    • Approach
    • Opioid Induced Respiratory Depression
    • Paediatric
    • CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  • News
  • Careers
  • Contact
PneumoWave

Remote Patient Monitoring
for Conditions Affecting
the Respiratory System

PneumoWave aims to transform the way patients with respiratory conditions manage their health and live their lives.

Learn More About PneumoWave

Patient-Centred Management of Respiratory Illness

Opioids

Opioid Epidemic

Learn about our platform for opioid induced respiratory depression.

Learn More

COPD

COPD

Learn about our platform for Chronic Obstructive Pulmonary Disease (COPD)

Learn More

Paediatric Monitoring

Paediatric Monitoring

Learn about our platform for paediatric respiratory monitoring.

Learn More

PneumoWave is an integrated platform of patient data capture and proprietary
analysis. Our solutions aim to facilitate a paradigm shift in respiratory care focusing
on intervention before disease or injury has advanced.

24/7 Respiratory Monitoring

Our small, chest-worn biosensor continuously captures data and transmits it wirelessly for analysis

Real Time Results

Proprietary algorithms aim to accurately detect a range of respiratory adverse events in real-time

Cloud Platform

Processed data can be viewed in our cloud platform, allowing clinicians to remotely provide personalized treatment

Urgent Unmet Medical Need

The Opioid Epidemic Poses An Urgent Unmet Medical Need

From 1999–2019, in the USA alone nearly 500,000 people died from an overdose involving any opioid, including prescription and illicit opioids.

Learn More

News

Keep updated on all PneumoWave’s news, events and latest press releases.

PneumoWave raises £7.5 million Series A to accelerate clinical validation and regulatory submission of respiratory change diagnosis and monitoring platform
Press Release
12 January 2023

PneumoWave raises £7.5 million Series A to accelerate clinical validation and regulatory submission of respiratory change diagnosis and monitoring platform

£5.2 m equity from Scottish National Investment Bank alongside £2.3 m from existing investors Scottish...
Today is Opioid Awareness Day
Uncategorized
30 August 2022

Today is Opioid Awareness Day

Today is Opioid Awareness Day. Our Chief Executive Officer and Founder Dr Bruce Henderson has...
PneumoWave Featured in the Scotsman
Press Release
20 June 2022

PneumoWave Featured in the Scotsman

We are delighted to be featured in the Scotsman newspaper: Digital health firm PneumoWave aiming...
Dr Gary Cooney appointed as Mental Health Lead
Press Release
20 April 2022

Dr Gary Cooney appointed as Mental Health Lead

PUBLISHED: APRIL 19, 2022 Digital health company PneumoWave today announced the appointment of Dr Gary...

Clinical Trial Partners

Uni Dundee logo
NHS logo
KCL logo
pneumowave logo colour

About PneumoWave

Contact

Privacy Policy

PneumoWave’s technology is currently undergoing development and evaluation in clinical trials. Performance characteristics have yet to be established.

Website by genapse